Axsome Therapeutics (AXSM) Rallies After Auvelity Gains FDA Approval

Cowen Reiterates Outperform, $130 PT on Axsome Therapeutics (AXSM) Following FDA Approval

August 19, 2022 10:39 AM EDT

Cowen analyst Joseph Thome reiterated an Outperform rating and $130.00 price target on Axsome Therapeutics (NASDAQ: AXSM) following news that AXS-05 (Auvelity) has been approved for the treatment of MDD nearly one year after the therapy's initial PDUFA date.

The analyst... More

Axsome's depression drug enters competitive market after U.S. approval

August 19, 2022 8:03 AM EDT

By Amruta Khandekar

(Reuters) -Axsome Therapeutics Inc on Friday gained U.S. approval for its treatment for depression, giving more than 20 million Americans affected by the disorder a new option in a market crowded by older drugs.

Shares of the U.S.-based company, which expects to launch the drug in the fourth quarter, surged 25% in early trade.

The drug, Auvelity, is a new class of treatment that reduces the symptoms... More

Axsome Therapeutics (AXSM) Climbs 40% Following FDA Approval of AUVELITY

August 19, 2022 7:23 AM EDT

Axsome Therapeutics (NASDAQ: AXSM) Climbs 40% Following FDA Approval of AUVELITY

... More

Axsome Therapeutics (AXSM) Announces FDA Approval of AUVELITY

August 19, 2022 6:46 AM EDT

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved AUVELITYTM (dextromethorphan HBr -bupropion HCl) extended-release tablets for the treatment of major depressive disorder (MDD) in adults.1 AUVELITY is the first and only rapid-acting oral medicine approved for the treatment of MDD with labeling of statistically significant antidepressant efficacy compared to placebo starting at one week.1-4 The rapid antidepressant effects of AUVELITY were sustained at all subsequent... More